Sciety flags revived US biotech IPO market as 20 listings raise USD 6.1 billion in 2026

Bitget2026/09/28 09:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sciety flagged a rebound in US biotech investor appetite, marked by stronger IPO issuance and broad sector gains.
20 US drug-development biotech IPOs priced through mid-August 2026, raising about USD 6.1 billion.
Six Nasdaq biopharma IPOs over the summer upsized, raising USD 1.6 billion.
Parabilis Medicines raised USD 670 million, described as the largest biotech IPO on record.
XBI was up more than 80% year-on-year by late August, pointing to improved sentiment.
Most 2026 IPO issuers were late-stage, with 15 companies at or near Phase 2 or later.
Europe and the Nordics could see a pickup in biotech demand in H1 2027 if the prior cycle’s lag repeats.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sciety AB published the original content used to generate this news brief on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sciety flags revived US biotech IPO market as 20 listings raise USD 6.1 billion in 2026

You may also like

Crypto prices